Cheaper medicines, free beach trips: U.S. health plans tap prescriptions that feds say are illegal

Alternative Funding Programs (AFPs) are rapidly expanding in the U.S. healthcare market, offering employers and patients significant savings on high-cost specialty drugs by sourcing them from overseas, often through unauthorized supply chains. While AFPs present a solution to exorbitant U.S. drug prices, federal authorities like Homeland Security and the FDA deem such personal importation of FDA-approved drugs illegal and a potential risk to patient safety due to unverified origins and quality. Pharmaceutical companies, including Gilead Sciences, are actively suing AFPs for diverting medications and disrupting authorized supply chains, leading to preliminary injunctions, as regulators and Congress express deep concern over the legality and safety implications for patients and the broader healthcare system.

Analysis

Alternative Funding Programs (AFPs) are gaining traction by offering significant cost savings on high-priced specialty medications, such as Biogen's Avonex and Gilead's Biktarvy, by sourcing them from overseas markets where prices are substantially lower (U.S. prices are nearly three times higher on average). This model, while attractive to employers and patients seeking relief from exorbitant drug costs, operates in a legally ambiguous and potentially risky environment, as federal authorities like Homeland Security and the FDA deem the commercial importation of FDA-approved drugs for personal use illegal.

The FDA explicitly states that medications from outside the legitimate U.S. drug supply chain lack assurances of safety, effectiveness, and quality. Pharmaceutical companies, including Gilead Sciences (GILD), are actively pursuing litigation against AFPs (e.g., Rx Valet, CANARX, ElectRx) for diverting their products and disrupting authorized supply chains, resulting in preliminary injunctions against these programs. Evidence, such as Turkish Customs data, reveals unauthorized rerouting of Biogen's (BIIB) Avonex, underscoring the integrity concerns within these supply chains.

The controversy extends to major healthcare players, with CVS Health's (CVS) Meritain Health implicated in Gilead's lawsuit, highlighting broader industry exposure to these practices. Congressional committees and patient advocacy groups, like the Cystic Fibrosis Foundation, are expressing deep concerns over patient safety, treatment delays (average 41 days for AFP users vs. 15 days for others), and the ethical implications of these programs, which are perceived as prioritizing cost savings over patient well-being. This collective scrutiny signals a potential for increased regulatory enforcement and legislative action.

Key Decisions for Investors

• Investors should closely monitor ongoing legal challenges and regulatory actions against AFPs, as outcomes could significantly impact pharmaceutical supply chains and drug pricing dynamics.
• Evaluate pharmaceutical companies' (e.g., BIIB, GILD) strategies for protecting intellectual property and authorized distribution channels against parallel trade, as successful enforcement could bolster their market positions.
• Assess the exposure of healthcare service providers, PBMs, and insurers (e.g., CVS) to AFPs, considering potential legal liabilities, reputational risks, and the need to re-evaluate contractual relationships.
• Consider the broader implications for U.S. drug pricing reform, as the rise of AFPs underscores systemic issues that may prompt policy changes affecting the entire pharmaceutical and healthcare sector.